ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
강심제 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 12.6%의 CAGR로 50억 6,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 심혈관계 사망률 증가, 강심제 강화에 초점을 맞춘 임상시험 증가, 심혈관계 약물 개발에 대한 민관 협력 확대, 심장 합병증으로 인한 입원 증가, 맞춤형 심혈관계 의료에 대한 수요 증가에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 펩타이드 기반 개발, 이중 기전 약물 개발, 약리유전체학 통합, 주사제형 디포제제 혁신, 병용요법의 발전 등이 있습니다.
심혈관질환의 유병률 증가는 향후 몇 년 동안 강심제 시장의 성장을 촉진할 것으로 예상됩니다. 심혈관질환(CVD)은 관상동맥질환, 심부전, 부정맥, 뇌졸중 등 심장과 혈관에 영향을 미치는 질환을 포함합니다. 이러한 증가는 포화지방산, 트랜스지방산, 염분, 당분을 많이 함유한 건강에 해로운 식습관이 주요 원인이며, 비만, 고혈압, 콜레스테롤 수치 상승의 한 원인이 되고 있습니다. 강심제는 심근의 효율과 수축력을 높여 혈액순환을 개선하고 다양한 심혈관계 질환의 증상을 완화합니다. 예를 들어, 2023년 12월 호주 정부 기관인 호주 보건 복지 연구소는 관상동맥성 심장 질환(CHD)으로 인한 의사 진단 사망자 수가 2021년 1만 4,100명에서 2022년 1만 4,900명으로 증가했다고 보고했습니다. 결과적으로 심혈관질환의 유병률 증가는 강심제 시장 성장에 기여하고 있습니다.
강심제 시장의 주요 기업들은 급성 심부전 및 심인성 쇼크의 심장 기능 개선을 목적으로 하는 단기 강심제와 같은 혁신적인 제품을 개발하고 있습니다. 단기 강심제는 심장의 수축력을 일시적으로 증가시키고 심박출량을 증가시키는 데 사용됩니다. 예를 들어, 2023년 6월 영국 제약회사 Hikma Pharmaceuticals plc는 250mg/20mL 바이알 용량의 도부타민 주사제 USP를 출시했습니다. 이 주사액은 심장 질환이나 심장 수술 후 흔히 발생하는 심장 수축력 저하로 인한 심근 탈락을 앓고 있는 성인에게 단기간의 강심 작용을 제공합니다. 도부타민은 베타1 수용체를 자극하여 심근 수축력과 심박출량을 1-2분 내에 빠르게 증가시킵니다. 이 주사는 정맥으로 투여되며, 보통 병원에서 엄격한 의학적 관리 하에 사용됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 강심제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 강심제 시장 : 성장률 분석
세계의 강심제 시장 실적 : 규모와 성장, 2019-2024년
세계의 강심제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 강심제 전체 시장(TAM)
제6장 시장 세분화
세계의 강심제 시장 : 약물 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
디기탈리스 배당체
포스포디에스테라제 억제제
심장 보호제
교감신경 자극제
기타
세계의 강심제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
정맥내
기타
세계의 강심제 시장 : 제형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
정제
용액
기타
세계의 강심제 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
심장외과 수술
심방세동
심부전
폐고혈압
기타
세계의 강심제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 강심제 시장 : 디기탈리스 배당체 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Digoxin
Digitoxin
Lanatoside C
세계의 강심제 시장 : 포스포디에스테라제 억제제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Milrinone
Enoximone
Amrinone
세계의 강심제 시장 : 심장 보호제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Coenzyme Q10
Dexrazoxane
Trimetazidine
세계의 강심제 시장 : 교감신경 자극제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Dobutamine
Dopamine
Norepinephrine
세계의 강심제 시장 : 기타 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Levosimendan
Omecamtiv Mecarbil
Cilostazol
제7장 지역별·국가별 분석
세계의 강심제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 강심제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
강심제 시장 : 경쟁 구도
강심제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bristol-Myers Squibb Company
AstraZeneca plc
Novartis AG
Eli Lilly and Company
Fresenius Kabi
Aurobindo Pharma Limited
Hikma Pharmaceuticals PLC
Alchem International Private Ltd
Farbe Firma Private Limited
Salius Pharma Pvt. Ltd.
Johnlee Pharmaceuticals Pvt. Ltd.
Healthy Life Pharma Pvt Ltd
Anwita Drugs
Varion Lifesciences
Deccan Nutraceuticals Pvt. Ltd
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
강심제 시장 2029년 : 새로운 기회를 제공하는 국가
강심제 시장 2029년 : 새로운 기회를 제공하는 부문
강심제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Cardiotonic agents are a group of drugs that enhance the strength and efficiency of heart muscle contractions, thereby improving the heart's ability to pump blood. These medications are primarily used to manage heart failure and certain arrhythmias by boosting cardiac output and enhancing blood circulation.
The main categories of cardiotonic agents include digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds extracted from the Digitalis plant, used to treat heart conditions by increasing contraction force and regulating heart rhythm. These drugs can be administered orally, intravenously, or via other methods, with common dosage forms including tablets and solutions. They are utilized in a variety of clinical scenarios such as cardiac surgeries, atrial fibrillation, heart failure, pulmonary hypertension, among others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The cardiotonic agents market research report is one of a series of new reports from The Business Research Company that provides cardiotonic agents market statistics, including cardiotonic agents industry global market size, regional shares, competitors with a cardiotonic agents market share, cardiotonic agents market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. This cardiotonic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiotonic agents market size has grown rapidly in recent years. It will grow from $2.78 billion in 2024 to $3.14 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historic period can be attributed to the rising prevalence of heart failure, an expanding elderly population, an increasing incidence of coronary artery disease, greater adoption of sedentary lifestyles, and the growing burden of hypertension and diabetes.
The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing cardiovascular mortality rates, a rise in clinical trials focused on enhanced cardiotonic formulations, expanding public-private collaborations in cardiovascular drug development, growing hospital admissions related to cardiac complications, and heightened demand for personalized cardiovascular medicine. Key trends during the forecast period include the development of peptide-based cardiotonic agents, creation of dual-mechanism drugs, integration of pharmacogenomics, innovation in injectable depot formulations, and advancement of combination therapies.
The increasing prevalence of cardiovascular diseases is expected to drive growth in the cardiotonic agents market in the coming years. Cardiovascular diseases (CVDs) include a group of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. This rise is largely attributed to unhealthy diets rich in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents work by enhancing the heart muscle's efficiency and contraction strength, thereby supporting improved blood circulation and alleviating symptoms in various cardiovascular conditions. For example, in December 2023, the Australian Institute of Health and Welfare, an Australian government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the cardiotonic agents market.
Leading companies in the cardiotonic agents market are developing innovative products, including short-term inotropic drugs, aimed at improving cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are used to temporarily increase the heart's contractility, which enhances cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection provides short-term inotropic support for adults suffering from cardiac decompensation due to reduced heart contractility, often caused by heart disease or following cardiac surgery. Dobutamine stimulates beta-1 receptors to boost heart muscle contractility and cardiac output with a rapid onset of 1 to 2 minutes. The injection is administered intravenously and is typically used in hospital settings under close medical supervision.
In April 2023, SK Capital Partners LP, a US-based capital market company, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed sum. This acquisition aims to accelerate Apotex's growth and innovation by leveraging SK Capital's expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures a cardiotonic agent marketed under the brand name Apo-Digoxin.
Major players in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, and Deccan Nutraceuticals Pvt. Ltd.
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiotonic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cardiotonic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiotonic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiotonic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cardiotonic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiotonic agents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Digitalis Glycosides; Phosphodiesterase Inhibitors; Cardioprotectants; Sympathomimetic Agents; Other Drug Types
2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
3) By Dosage Form: Tablet; Solution; Other Dosage Forms
4) By Application: Cardiac Surgical Procedures; Atrial Fibrillation; Heart Failure; Pulmonary Hypertension; Other Applications
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Digitalis Glycoside: Digoxin; Digitoxin; Lanatoside C
2) By Phosphodiesterase Inhibitors: Milrinone; Enoximone; Amrinone
3) By Cardioprotectants: Coenzyme Q10; Dexrazoxane; Trimetazidine
4) By Sympathomimetic Agents: Dobutamine; Dopamine; Norepinephrine
5) By Other Drug Types: Levosimendan; Omecamtiv Mecarbil; Cilostazol
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cardiotonic Agents Market Characteristics
3. Cardiotonic Agents Market Trends And Strategies
4. Cardiotonic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Cardiotonic Agents Growth Analysis And Strategic Analysis Framework
5.1. Global Cardiotonic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cardiotonic Agents Market Growth Rate Analysis
5.4. Global Cardiotonic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cardiotonic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cardiotonic Agents Total Addressable Market (TAM)
6. Cardiotonic Agents Market Segmentation
6.1. Global Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Digitalis Glycosides
Phosphodiesterase Inhibitors
Cardioprotectants
Sympathomimetic Agents
Other Drug Types
6.2. Global Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Other Route Of Administrations
6.3. Global Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Solution
Other Dosage Forms
6.4. Global Cardiotonic Agents Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiac Surgical Procedures
Atrial Fibrillation
Heart Failure
Pulmonary Hypertension
Other Applications
6.5. Global Cardiotonic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global Cardiotonic Agents Market, Sub-Segmentation Of Digitalis Glycosides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Digoxin
Digitoxin
Lanatoside C
6.7. Global Cardiotonic Agents Market, Sub-Segmentation Of Phosphodiesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Milrinone
Enoximone
Amrinone
6.8. Global Cardiotonic Agents Market, Sub-Segmentation Of Cardioprotectants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Coenzyme Q10
Dexrazoxane
Trimetazidine
6.9. Global Cardiotonic Agents Market, Sub-Segmentation Of Sympathomimetic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dobutamine
Dopamine
Norepinephrine
6.10. Global Cardiotonic Agents Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Levosimendan
Omecamtiv Mecarbil
Cilostazol
7. Cardiotonic Agents Market Regional And Country Analysis
7.1. Global Cardiotonic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cardiotonic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cardiotonic Agents Market
9.1. China Cardiotonic Agents Market Overview
9.2. China Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cardiotonic Agents Market
10.1. India Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cardiotonic Agents Market
11.1. Japan Cardiotonic Agents Market Overview
11.2. Japan Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cardiotonic Agents Market
12.1. Australia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cardiotonic Agents Market
13.1. Indonesia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cardiotonic Agents Market
14.1. South Korea Cardiotonic Agents Market Overview
14.2. South Korea Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cardiotonic Agents Market
15.1. Western Europe Cardiotonic Agents Market Overview
15.2. Western Europe Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cardiotonic Agents Market
16.1. UK Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cardiotonic Agents Market
17.1. Germany Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cardiotonic Agents Market
18.1. France Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cardiotonic Agents Market
19.1. Italy Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cardiotonic Agents Market
20.1. Spain Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cardiotonic Agents Market
21.1. Eastern Europe Cardiotonic Agents Market Overview
21.2. Eastern Europe Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cardiotonic Agents Market
22.1. Russia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cardiotonic Agents Market
23.1. North America Cardiotonic Agents Market Overview
23.2. North America Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cardiotonic Agents Market
24.1. USA Cardiotonic Agents Market Overview
24.2. USA Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Cardiotonic Agents Market
25.1. Canada Cardiotonic Agents Market Overview
25.2. Canada Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cardiotonic Agents Market
26.1. South America Cardiotonic Agents Market Overview
26.2. South America Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cardiotonic Agents Market
27.1. Brazil Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cardiotonic Agents Market
28.1. Middle East Cardiotonic Agents Market Overview
28.2. Middle East Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cardiotonic Agents Market
29.1. Africa Cardiotonic Agents Market Overview
29.2. Africa Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cardiotonic Agents Market Competitive Landscape And Company Profiles
